Literature DB >> 30419802

The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer.

Marjorie De la Fuente López1,2, Glauben Landskron2, Daniela Parada2, Karen Dubois-Camacho2, Daniela Simian1, Maripaz Martinez1, Diego Romero3, Juan Carlos Roa3, Isidora Chahuán2, Rocío Gutiérrez2, Francisco Lopez-K4, Karin Alvarez4, Udo Kronberg4, Sebastian López5, Antonella Sanguinetti5, Natalia Moreno5, Mario Abedrapo5, María-Julieta González6, Rodrigo Quera7, Marcela A Hermoso-R2.   

Abstract

A complex network of chemokines can influence cancer progression with the recruitment and activation of hematopoietic cells, including macrophages to the supporting tumor stroma promoting carcinogenesis and metastasis. The aim of this study was to investigate the relation between tissue and plasma chemokine levels involved in macrophage recruitment with tumor-associated macrophage profile markers and clinicopathological features such as tumor-node-metastases stage, desmoplasia, tumor necrosis factor-α, and vascular endothelial growth factor plasma content. Plasma and tumor/healthy mucosa were obtained from Chilean patients undergoing colon cancer surgery. Chemokines were evaluated from tissue lysates (CCL2, CCL3, CCL4, CCL5, and CX3CL1) by Luminex. Statistical analysis was performed using Wilcoxon match-paired test ( p  < 0.05). Macrophage markers (CD68, CD163, and iNOS) were evaluated by immunohistochemistry samples derived from colorectal cancer patients. Correlation analysis between chemokines and macrophage markers and clinicopathological features were performed using Spearman's test. Plasmatic levels of chemokines and inflammatory mediators' vascular endothelial growth factor and tumor necrosis factor-α were evaluated by Luminex. Tumor levels of CCL2 (mean ± standard deviation = 530.1 ± 613.9 pg/mg), CCL3 (102.7 ± 106.0 pg/mg), and CCL4 (64.98 ± 48.09 pg/mg) were higher than those found in healthy tissue (182.1 ± 116.5, 26.79 ± 22.40, and 27.06 ± 23.69 pg/mg, respectively p < 0.05). The tumor characterization allowed us to identify a positive correlation between CCL4 and the pro-tumor macrophages marker CD163 ( p  = 0.0443), and a negative correlation of iNOS with desmoplastic reaction ( p  = 0.0467). Moreover, we identified that tumors with immature desmoplasia have a higher CD163 density compared to those with a mature/intermediated stromal tissue ( p  = 0.0288). Plasmatic CCL4 has shown a positive correlation with inflammatory mediators (tumor necrosis factor-α and vascular endothelial growth factor) that have previously been associated with poor prognosis in patients. In conclusion High expression of CCL4 in colon cancer could induce the infiltration of tumor-associated macrophages and specifically a pro-tumor macrophage profile (CD163+ cells). Moreover, plasmatic chemokines could be considered inflammatory mediators associated to CRC progression as well as tumor necrosis factor-α and vascular endothelial growth factor. These data reinforce the idea of chemokines as potential therapeutic targets or biomarker in CRC.

Entities:  

Keywords:  Colorectal cancer; chemokines; macrophages; tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 30419802     DOI: 10.1177/1010428318810059

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

Review 1.  The complex role of tumor-infiltrating macrophages.

Authors:  Anthos Christofides; Laura Strauss; Alan Yeo; Carol Cao; Alain Charest; Vassiliki A Boussiotis
Journal:  Nat Immunol       Date:  2022-07-25       Impact factor: 31.250

Review 2.  Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer.

Authors:  Jing Xu; Jing-Quan Li; Qi-Lei Chen; Elena A Shestakova; Vsevolod A Misyurin; Vadim S Pokrovsky; Elena M Tchevkina; Hu-Biao Chen; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

3.  Single-Cell Analysis Unveils the Role of the Tumor Immune Microenvironment and Notch Signaling in Dormant Minimal Residual Disease.

Authors:  Mahnaz Janghorban; Yuchen Yang; Na Zhao; Clark Hamor; Tuan M Nguyen; Xiang H-F Zhang; Jeffrey M Rosen
Journal:  Cancer Res       Date:  2022-03-01       Impact factor: 13.312

4.  A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells.

Authors:  Alejandro Schcolnik-Cabrera; Guadalupe Dominguez-Gómez; Alma Chávez-Blanco; Marisol Ramírez-Yautentzi; Rocío Morales-Bárcenas; José Chávez-Díaz; Lucía Taja-Chayeb; Alfonso Dueáas-González
Journal:  Oncol Lett       Date:  2019-10-18       Impact factor: 2.967

5.  Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.

Authors:  Mitsukuni Suenaga; W U Zhang; Tetsuo Mashima; Marta Schirripa; Shu Cao; Satoshi Okazaki; Martin D Berger; Yuji Miyamoto; Afsaneh Barzi; Toshiharu Yamaguchi; Heinz-Josef Lenz
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

Review 6.  Monocyte Regulation in Homeostasis and Malignancy.

Authors:  Amy Robinson; Claudia Z Han; Christopher K Glass; Jeffrey W Pollard
Journal:  Trends Immunol       Date:  2021-01-11       Impact factor: 16.687

7.  Correlation analysis of expression of CC and CXC chemokines in children with autism spectrum disorder.

Authors:  Guangyang Peng; Xiaofei Peng; Tingting Tong; Xiuyun Zhang; Min Xu; Xiaofang Peng
Journal:  Medicine (Baltimore)       Date:  2021-06-18       Impact factor: 1.817

Review 8.  Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.

Authors:  Jing Jin; Qijie Zhao
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

9.  CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling.

Authors:  Renlun Huang; Shengqi Wang; Neng Wang; Yifeng Zheng; Jianfu Zhou; Bowen Yang; Xuan Wang; Juping Zhang; Lang Guo; Shusheng Wang; Zhiqiang Chen; Zhiyu Wang; Songtao Xiang
Journal:  Cell Death Dis       Date:  2020-04-16       Impact factor: 8.469

10.  Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation.

Authors:  Payal Dhar; Fahmin Basher; Zhe Ji; Lei Huang; Si Qin; Derek A Wainwright; Jerid Robinson; Shaye Hagler; Jing Zhou; Sean MacKay; Jennifer D Wu
Journal:  Commun Biol       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.